Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Halabi

Showing results (251-260 of 282) with videos related to

Pageof 29
Sort By:
European Urology Oncology|July 19, 2025
Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate CancerSoumyajit Roy, Yilun Sun, James A Eastham, et al.
Cancer|May 5, 2021
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancerDaniel J George, Susan Halabi, Elisabeth I Heath, et al.
JCO Precision Oncology|January 15, 2026
Olaparib in Patients With Solid Tumors With <i>ATM</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyDaniel R Carrizosa, Michael Rothe, Pam K Mangat, et al.
Nature Communications|December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerSoumyajit Roy, Yilun Sun, Maha Hussain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2016
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced NeuropathyDaniel L Hertz, Kouros Owzar, Sherrie Lessans, et al.
JAMA Network Open|January 16, 2026
Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate CancerPedro C Barata, June K Corrigan, Jennifer La, et al.
Lancet (London, England)|April 7, 2024
The Lancet Commission on prostate cancer: planning for the surge in casesNicholas D James, Ian Tannock, James N'Dow, et al.
JAMA Oncology|May 24, 2019
Association of Black Race With Prostate Cancer-Specific and Other-Cause MortalityRobert T Dess, Holly E Hartman, Brandon A Mahal, et al.
The New England Journal of Medicine|September 16, 2024
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial CarcinomaAndrea B Apolo, Karla V Ballman, Guru Sonpavde, et al.
Prostate Cancer and Prostatic Diseases|August 7, 2021
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancerVadim S Koshkin, Vaibhav G Patel, Alicia Ali, et al.
Pageof 29

Showing results (251-260 of 282) with videos related to

Sort By:
Pageof 29
European Urology Oncology|July 19, 2025
Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate CancerSoumyajit Roy, Yilun Sun, James A Eastham, et al.
Cancer|May 5, 2021
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancerDaniel J George, Susan Halabi, Elisabeth I Heath, et al.
JCO Precision Oncology|January 15, 2026
Olaparib in Patients With Solid Tumors With <i>ATM</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyDaniel R Carrizosa, Michael Rothe, Pam K Mangat, et al.
Nature Communications|December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerSoumyajit Roy, Yilun Sun, Maha Hussain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2016
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced NeuropathyDaniel L Hertz, Kouros Owzar, Sherrie Lessans, et al.
JAMA Network Open|January 16, 2026
Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate CancerPedro C Barata, June K Corrigan, Jennifer La, et al.
Lancet (London, England)|April 7, 2024
The Lancet Commission on prostate cancer: planning for the surge in casesNicholas D James, Ian Tannock, James N'Dow, et al.
JAMA Oncology|May 24, 2019
Association of Black Race With Prostate Cancer-Specific and Other-Cause MortalityRobert T Dess, Holly E Hartman, Brandon A Mahal, et al.
The New England Journal of Medicine|September 16, 2024
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial CarcinomaAndrea B Apolo, Karla V Ballman, Guru Sonpavde, et al.
Prostate Cancer and Prostatic Diseases|August 7, 2021
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancerVadim S Koshkin, Vaibhav G Patel, Alicia Ali, et al.
Pageof 29